Business Context and Reporting Period
Company: Artelo Biosciences, Inc. (ARTL)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Artelo is a clinical-stage biopharmaceutical company developing therapeutics targeting lipid-signaling pathways, including the endocannabinoid system (ECS). Key programs include ART27.13 (cancer-related anorexia), ART26.12 (chemotherapy-induced peripheral neuropathy), and ART12.11 (CBD cocrystal). The company has incurred losses since inception and has not generated revenue.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(5,385) | $(5,593) |
| Operating Expenses | $5,194 | $5,529 |
| Cash and Cash Equivalents (End of Period) | $4,198 | $2,066 |
| Net Cash Used in Operating Activities | $(6,224) | $(2,111) |
| Net Cash Provided by Financing Activities | $9,796 | $1,816 |
| Working Capital | $2,916 | $(3,349) |
Note: The company reported a net loss per share of $(3.11) for the six months ended June 30, 2026, compared to $(29.44) in the prior year period. The significant improvement in EPS is largely due to a reverse stock split and increased share count.
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased from $600,000 at December 31, 2025, to $4,198,000 at June 30, 2026. This was driven by a private placement offering in March 2026 yielding net proceeds of approximately $10.0 million and an At-The-Market (ATM) offering.
- Debt Extinguishment: The company settled all outstanding convertible notes (including related party notes) during the period. Total repayments and conversions amounted to approximately $1.2 million in cash and $208,000 in equity conversion. A gain on extinguishment of debt of $42,000 was recorded.
- Expense Reduction: Total operating expenses decreased by $335,000 compared to the prior year, primarily due to a $1.6 million reduction in Research and Development (R&D) expenses. This decrease was partially offset by a $1.3 million increase in General and Administrative (G&A) expenses, driven by higher professional fees related to financing activities and increased stock-based compensation.
- Capital Structure: The company executed a 1-for-3 reverse stock split effective March 10, 2026. Outstanding shares increased from 673,008 (Dec 31, 2025) to 4,188,400 (June 30, 2026) due to equity issuances.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. The company expects to continue incurring losses and will require additional funding through equity or debt offerings or licensing to sustain operations.
- Financing Activities:
- Private Placement: Closed March 30, 2026, raising gross proceeds of ~$11.0 million (net ~$10.0 million) via common stock, pre-funded warrants, and common warrants.
- ATM Facility: Established May 26, 2026, allowing sales of up to $6.53 million of common stock. As of June 30, 2026, $174,000 in net proceeds were generated.
- Equity Line: An equity purchase agreement allows for up to $25.0 million in additional funding.
- Product Development:
- ART27.13: Interim Phase 2a results showed a mean weight gain of 6.38% in treated patients vs. 5.42% loss in placebo for cancer anorexia.
- ART26.12: Completed Phase 1 Single Ascending Dose study in healthy volunteers with no drug-related adverse events.
- Risks: Key risks include the inability to raise additional capital, the uncertainty of clinical trial outcomes, and the impact of global economic conditions and geopolitical conflicts on operations and supply chains.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.2 million cash balance against projected operating burn rates, given the "substantial doubt" going concern disclosure.
- Dilution Impact: Assess the dilution from the recent private placement (3.1 million pre-funded warrants and 6.4 million common warrants issued) and the potential exercise of the ATM facility.
- Debt Status: Confirm that all convertible notes and related party debt have been fully extinguished as reported, and review terms of any new debt instruments.
- Clinical Milestones: Monitor upcoming data readouts for ART27.13 (CAReS trial) and ART26.12 to validate the commercial potential of the pipeline.
- Stock Split Adjustments: Ensure all historical share counts and per-share metrics are adjusted for the 1-for-3 reverse stock split effective March 2026.